Trial Profile
SCH 52365 Phase II Clinical Study: A Study on the Efficacy and Safety of Monotherapy With SCH 52365 in Patients With First Relapsed Anaplastic Astrocytoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 May 2022
Price :
$35
*
At a glance
- Drugs Temozolomide (Primary)
- Indications Anaplastic astrocytoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Merck Sharp & Dohme; Schering-Plough
- 16 Nov 2008 New trial record.